NeuBase Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NBSE and buy or sell other stocks, ETFs, and their options commission-free!About NBSE
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines.
CEOTodd P. Branning, MBA, CPA
CEOTodd P. Branning, MBA, CPA
Employees—
Employees—
HeadquartersPittsburgh, Pennsylvania
HeadquartersPittsburgh, Pennsylvania
Founded2009
Founded2009
Employees—
Employees—
NBSE Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.45
52 Week high$0.45
52 Week low$0.36
52 Week low$0.36
Stock Snapshot
NeuBase Therapeutics(NBSE) trades at $0.38.
NeuBase Therapeutics(NBSE) stock opened on 2026-02-17 at —. The price climbed to — and dipped to —.
The NeuBase Therapeutics(NBSE)'s current trading volume is 0.
In the last year, NeuBase Therapeutics(NBSE) shares hit a 52-week high of $0.45 and a 52-week low of $0.36.
In the last year, NeuBase Therapeutics(NBSE) shares hit a 52-week high of $0.45 and a 52-week low of $0.36.
People also own
Based on the portfolios of people who own NBSE. This list is generated using Robinhood data, and it’s not a recommendation.